Table 1.
Baseline table for all 1,200 included patients with metastatic cancer.
| Patient characteristics | N = 1,200 |
|---|---|
| Age at WGS, years | |
| Mean | 59.3 |
| Range | 18–98 |
| Sex, male:female | 43:57 |
| Primary tumor location, n (%) | |
| Lung cancer | 344 (29%) |
| Colorectal cancer | 210 (18%) |
| Breast cancer | 143 (12%) |
| Sarcoma | 80 (6.7%) |
| Other | 67 (5.6%) |
| Prostate cancer | 47 (3.9%) |
| CUP | 34 (2.8%) |
| Ovarian cancer | 32 (2.7%) |
| Melanoma | 29 (2.4%) |
| Bladder cancer | 25 (2.1%) |
| Lung NETs | 23 (1.9%) |
| Esophageal cancer | 21 (1.8%) |
| Renal cell cancer | 19 (1.6%) |
| Head and neck cancer | 14 (1.2%) |
| Stomach cancer | 13 (1.1%) |
| GEP‐NETs | 13 (1.1%) |
| Cervical cancer | 11 (0.92%) |
| GIST | 10 (0.83%) |
| Malignant mesothelioma | 9 (0.75%) |
| Urothelial cell cancer of the bladder and renal pelvis | 8 (0.67%) |
| Anal cancer | 7 (0.58%) |
| Thymoma and thymic cancer | 7 (0.58%) |
| Vulva cancer | 6 (0.50%) |
| Penile cancer | 6 (0.50%) |
| Pancreatic cancer | 5 (0.42%) |
| Endometrial cancer | 4 (0.33%) |
| Lymphoma | 4 (0.33%) |
| Cholangiocarcinoma | 3 (0.25%) |
| Thyroid cancer | 3 (0.25%) |
| Basal cell carcinoma | 2 (0.17%) |
| Hepatocellular carcinoma | 1 (0.083%) |
CUP, cancer of unknown primary; GEP‐NETs, gastroenteropancreatic neuroendocrine tumors; GIST, gastrointestinal stromal tumor; NET, neuroendocrine tumor; WGS, whole‐genome sequencing.